High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention

N J Breet,J C Kelder,H J Bouman,C M Hackeng,J W Van Werkum,A M Harmsze,J M Ten Berg

doi:10.1136/hrt.2010.220491

High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention

N J Breet, J C Kelder + Show 5 more

https://doi.org/10.1136/hrt.2010.220491

Copy DOI

Journal: Heart	Publication Date: Apr 8, 2011
Citations: 95

Affiliation: St. Antonius Ziekenhuis

#High On-treatment Platelet Reactivity #High On-aspirin Platelet Reactivity + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

AimHigh on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are associated with atherothrombotic events following coronary stenting. There are, however, few data concerning high on-treatment platelet reactivity to...

Full Text